Brokerages Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) Will Announce Earnings of -$1.57 Per Share

Equities analysts predict that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post ($1.57) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for TRACON Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.64) and the highest is ($1.50). TRACON Pharmaceuticals posted earnings per share of ($2.60) in the same quarter last year, which would suggest a positive year over year growth rate of 39.6%. The firm is expected to issue its next quarterly earnings results on Thursday, February 27th.

On average, analysts expect that TRACON Pharmaceuticals will report full-year earnings of ($7.75) per share for the current year, with EPS estimates ranging from ($7.89) to ($7.60). For the next year, analysts forecast that the business will report earnings of ($1.24) per share, with EPS estimates ranging from ($4.48) to $2.00. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover TRACON Pharmaceuticals.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.03.

Several equities research analysts have weighed in on TCON shares. Zacks Investment Research upgraded shares of TRACON Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of TRACON Pharmaceuticals in a research note on Thursday, November 7th.

TCON stock traded down $0.07 during mid-day trading on Thursday, reaching $3.12. The company had a trading volume of 29,200 shares, compared to its average volume of 33,685. The company has a market capitalization of $10.00 million, a PE ratio of -0.24 and a beta of 2.28. TRACON Pharmaceuticals has a 12 month low of $2.78 and a 12 month high of $17.30. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.58 and a quick ratio of 1.58. The firm has a 50 day moving average of $0.81 and a 200 day moving average of $0.64.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new position in shares of TRACON Pharmaceuticals in the second quarter worth $26,000. Wedbush Securities Inc. purchased a new position in shares of TRACON Pharmaceuticals in the second quarter worth $32,000. Finally, Renaissance Technologies LLC raised its holdings in shares of TRACON Pharmaceuticals by 17.5% in the second quarter. Renaissance Technologies LLC now owns 1,209,203 shares of the biopharmaceutical company’s stock worth $822,000 after buying an additional 179,718 shares during the last quarter. Institutional investors own 54.72% of the company’s stock.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.

Further Reading: Convertible Shares

Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.